Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cadrenal Therapeutics, Inc. - Common Stock
(NQ:
CVKD
)
5.520
-0.180 (-3.16%)
Streaming Delayed Price
Updated: 3:15 PM EST, Feb 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cadrenal Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Why Is Cadrenal Therapeutics Stock Drawing Retail Attention Today?
↗
January 19, 2026
The company said VLX-1005 targets a high-risk heparin complication with limited treatment options.
Via
Stocktwits
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System
December 30, 2025
Via
ACCESS Newswire
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On
December 29, 2025
Via
ACCESS Newswire
Cadrenal's Quiet Expansion Play Is Starting to Get Loud
December 12, 2025
Via
ACCESS Newswire
Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million
↗
September 15, 2025
Via
Stocktwits
Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market
December 12, 2025
Via
ACCESS Newswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
September 17, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
September 10, 2025
Via
Benzinga
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 11, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
August 05, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
July 15, 2025
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
July 14, 2025
Via
Benzinga
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
June 12, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
June 04, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
May 15, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)
May 13, 2025
Via
Get News
Topics
Death
Economy
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
May 08, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
April 03, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
March 13, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
March 04, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
February 06, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
February 05, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
January 09, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
December 31, 2024
From
Cadrenal Therapeutics
Via
Business Wire
Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings
December 18, 2024
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
December 13, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
November 04, 2024
Via
Benzinga
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
↗
September 12, 2024
Via
Benzinga
Sidoti Events, LLC's Virtual August Micro-Cap Conference
August 13, 2024
Via
ACCESSWIRE
CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024
↗
August 07, 2024
CVKD stock results show that Cadrenal Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
